

Operates medical information media and provides business efficiency solutions for medical institutions

This report is an English translation of part of the report issued on December 30, 2022.
For inquiries concerning the report, please contact info@stock-r.org

[9341 GENOVA Sector : Services]

Fiscal Year	Net sales (mn yen)	YoY (%)	Operating profit (mn yen)	YoY (%)	Ordinary profit (mn yen)	YoY (%)	Profit (mn yen)	YoY (%)	EPS (yen)	BPS (yen)	DPS (yen)
Mar.2021	3,768	-	799	-	804	-	629	-	39.9	48.7	0.0
Mar.2022	4,802	27.4	1,054	32.0	1,059	31.7	686	9.0	43.0	91.9	0.0
Mar.2023 f	6,431	33.9	1,622	53.8	1,616	52.5	1,006	46.7	62.1	-	0.0

Note: Consolidated basis. Figures for the fiscal year ending March 2023 are the company's forecasts.

It conducted 1-to-10 stock split on June 10, 2021, and 1-to-200 stock split on August 19, 2022. Per share indices are adjusted retroactively.

Develops Media Management and Other Services for Medical Institutions

GENOVA operates medical media and provides operational efficiency and other solutions to medical institutions. Since its establishment in 2005, the company has been engaged in website production for medical institutions, and as of the end of fiscal year ended March 2022, it had a cumulative track record of about 11,000 transactions with medical institutions.

The company's main businesses are the medical platform business, which accounts for approximately 60% of net sales, and the smart clinic business, which accounts for slightly less than 30% of sales. The remainder is website production for medical institutions, a business that GENOVA has been operating since its founding, but the company is not actively seeking orders for new projects.

Medical Platform Business

In the medical platform business, GENOVA operates Medical DOC, a medical information media that distributes free of charge medical information and content on health issues that may be of interest to general users.

The media has a database of information on medical institutions nationwide and a search function so that the general users can search for the medical institution they are looking for.

For medical institutions, Medical DOC can be used to attract customers by introducing their own hospitals and treatment methods. GENOVA undertakes the production of articles posted on media introducing medical institutions, and the production fees paid by medical institutions are the main source of revenue for the medical platform business.

Smart Clinic Business

The smart clinic business provides services that help reduce the workload at medical institution sites.

The business is centered on the NOMOCa series, which consists of a smart simple automatic payment machine/reception machine for non-bed clinics and an automatic accounting and change dispenser machine that allows patients to insert money themselves. The equipment is manufactured by an outside contractor and sold through eight sales offices and a network of distributors. As of October 2022, 1,274 units of the NOMOCa series had been installed.

GENOVA (9341 TSE Growth) ----- January 12, 2023**Financial Statements**

Statement of income	Fiscal Year	Mar.2021		Mar.2022		Six months to Sep. 2022	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Net sales		3,768	100.0	4,802	100.0	2,916	100.0
Cost of sales		1,139	30.2	1,304	27.2	769	26.4
Gross profit		2,628	69.8	3,497	72.8	2,146	73.6
Selling, general and administrative expenses		1,829	48.6	2,442	50.9	1,451	49.8
Operating profit		799	21.2	1,054	22.0	695	23.9
Non-operating income		9	-	11	-	4	-
Non-operating expenses		3	-	6	-	1	-
Ordinary profit		804	21.3	1,059	22.1	699	24.0
Profit before income taxes		804	21.3	1,058	22.1	702	24.1
Profit attributable to owners of parent		629	16.7	686	14.3	438	15.0

Balance sheet	Fiscal Year	Mar.2021		Mar.2022		Sep. 2022	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets		1,622	86.6	2,440	86.6	2,650	86.6
Cash and deposits		1,166	62.3	1,654	58.7	1,893	61.9
Accounts receivable-trade		393	21.0	723	25.6	680	22.3
Prepaid expenses		30	1.6	24	0.9	n.a.	-
Non-current assets		251	13.4	378	13.4	409	13.4
Property, plant and equipment		26	1.4	107	3.8	134	4.4
Intangible assets		5	0.3	5	0.2	5	0.2
Investments and other assets		219	11.7	265	9.4	269	8.8
Total assets		1,873	100.0	2,819	100.0	3,060	100.0
Current liabilities		1,030	55.0	1,231	43.7	1,080	35.3
Accounts payable - trade		86	4.6	110	3.9	86	2.8
Non-current liabilities		65	3.5	95	3.4	47	1.6
Net assets		776	41.5	1,492	52.9	1,931	63.1
Owners' equity		768	41.0	1,487	52.7	1,925	62.9

Statement of cash flows	Fiscal Year	Mar.2021	Mar.2022	Six months to Sep. 2022
		(mn yen)	(mn yen)	(mn yen)
Cash flows from operating activities		1,056	623	433
Depreciation		12	37	22
Cash flows from investing activities		-68	-179	-71
Cash flows from financing activities		-75	59	-109
Dividends paid		-	-	-
Net increase in cash and cash equivalents		913	506	253
Cash and cash equivalents		1,151	1,639	1,893

Note: Consolidated

Source: Prepared by Stock Research Center based on the notifiable prospectus.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■ Supporting Members

Tokyo Stock Exchange, Inc.	SMBC Nikko Securities Inc.	Daiwa Securities Co. Ltd.
Nomura Securities Co., Ltd.	Mizuho Securities Co., Ltd.	Ernst & Young ShinNihon LLC
KPMG AZSA LLC	ICMG Co., Ltd.	Grant Thornton Taiyo LLC
Deloitte Touche Tohmatsu LLC	SBI SECURITIES Co., Ltd.	BDO Sanyu
Pricewaterhouse Coopers Kyoto	J Trust Global Securities Co., Ltd.	Ichiyoshi Securities Co., Ltd.
A&A Partners	GYOSEI & CO.	Avantia G.P.
TAKARA PRINTING CO., LTD.	PRONEXUS INC.	Japan Securities Dealers Association

The Securities Analysts Association of Japan

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.